• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis
This study aimed to determine the impact of iron chelation with deferoxamine (DFX) on (1) cerebral vascularization patterns and (2) functional outcomes after stroke in control and diabetic rats. After 8  weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests. Vas cular indices (vascular volume and surface area), neurovascular remodeling (AQP4 polarity), and microglia activation were meas...
Source: Translational Stroke Research - August 31, 2020 Category: Neurology Source Type: research

Role of Ferroptosis in Stroke
Cell Mol Neurobiol. 2022 Jan 31. doi: 10.1007/s10571-022-01196-6. Online ahead of print.ABSTRACTStroke is a common and serious nervous system disease caused by the rupture or blockage of the cardiovascular system. It causes millions of deaths and disabilities every year, which is a huge burden on humanity. It may be induced by thrombosis, hypertension, hyperlipidemia, hyperglycemia, smoking, advanced age and so on. According to different causes, stroke can be generally divided into hemorrhagic stroke and ischemic stroke, whose pathogenesis and treatment are quite different. Ferroptosis is a new type of cell death first def...
Source: Cellular and Molecular Neurobiology - February 1, 2022 Category: Cytology Authors: Yunfei Xu Kexin Li Yao Zhao Lin Zhou Ying Liu Jie Zhao Source Type: research

Comparison of Arterial Ischemic and Hemorrhagic Pediatric Stroke in Etiology, Risk Factors, Clinical Manifestations, and Prognosis
Conclusions Moyamoya disease/syndrome and arteriovenous malformation rapture are the most common cause of AIS and HS, respectively. Iron deficiency anemia was commonly found in childhood AIS. The time to diagnosis in both AIS and HS was delayed. The mortality rate in HS was higher than in AIS. Neurological deficits are seen in 70% of childhood AIS during the follow-up. One-third of the children in our study developed epilepsy, which generally responds to a single antiseizure medication. The recurrence rate of childhood stroke was low compared with adult stroke.
Source: Pediatric Emergency Care - September 1, 2022 Category: Emergency Medicine Tags: Original Articles Source Type: research

Iron Pathophysiology in Stroke.
Authors: Almutairi MMA, Xu G, Shi H Abstract Ischemic and hemorrhagic stroke are the common types of stroke that lead to brain injury neurological deficits and mortality. All forms of stroke remain a serious health issue, and there is little successful development of drugs for treating stroke. Incomplete understanding of stroke pathophysiology is considered the main barrier that limits this research progress. Besides mitochondria and free radical-producing enzymes, labile iron is an important contributor to oxidative stress. Although iron regulation and metabolism in cerebral stroke are not fully understood, much p...
Source: Advances in Experimental Medicine and Biology - August 29, 2019 Category: Research Tags: Adv Exp Med Biol Source Type: research

Iron chelators for acute stroke.
CONCLUSIONS: We identified two eligible RCTs for assessment. We could not demonstrate any benefit for the use of iron chelators in spontaneous intracerebral haemorrhage. The added value of iron-chelating therapy in people with ischaemic stroke or subarachnoid haemorrhage remains unknown. PMID: 33236783 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 24, 2020 Category: General Medicine Authors: Van der Loo LE, Aquarius R, Teernstra O, Klijn K, Menovsky T, van Dijk JMC, Bartels R, Boogaarts HD Tags: Cochrane Database Syst Rev Source Type: research

Inhibiting ferroptosis: A novel approach for stroke therapeutics.
Abstract Stroke ranks as the second leading cause of death across the globe. Despite advances in stroke therapeutics, no US Food and Drug Administration (FDA)-approved drugs that can minimize neuronal injury and restore neurological function are clinically available. Ferroptosis, a regulated iron-dependent form of nonapoptotic cell death, has been shown to contribute to stroke-mediated neuronal damage. Inhibitors of ferroptosis have also been validated in several stroke models of ischemia or intracerebral hemorrhage. Herein, we review the therapeutic activity of inhibitors of ferroptosis in stroke models. We furth...
Source: Drug Discovery Today - January 4, 2021 Category: Drugs & Pharmacology Authors: Jin Y, Zhuang Y, Liu M, Che J, Dong X Tags: Drug Discov Today Source Type: research

Deferoxamine Prevents Post-Stroke Memory Impairment in Female Diabetic Rats: Potential Links to Hemorrhagic Transformation and Ferroptosis
Am J Physiol Heart Circ Physiol. 2022 Dec 23. doi: 10.1152/ajpheart.00490.2022. Online ahead of print.ABSTRACTDiabetes increases the risk of post-stroke cognitive impairment (PSCI). Greater hemorrhagic transformation (HT) after stroke is associated with vasoregression and cognitive decline in male diabetic rats. Iron chelator deferoxamine (DFX) prevents vasoregression and improves outcomes. While diabetic female rats develop greater HT, its impact on post-stroke cerebrovascularization and cognitive outcomes remained unknown. We hypothesized that diabetes mediates pathological neovascularization, and DFX attenuates post-str...
Source: American Journal of Physiology. Heart and Circulatory Physiology - December 23, 2022 Category: Physiology Authors: Weiguo Li Yasir Abdul Raghavendar Chandran Sarah Jamil Rebecca A Ward Mohammed Abdelsaid Guangkuo Dong Susan C Fagan Adviye Ergul Source Type: research

Pages: 1  2  3  4  5  6  7